Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults

Gema Ariceta1,2, Enrique Lara1, Juan A. Camacho3, Federico Oppenheimer4, Julia Vara5, Fernando Santos6, Miguel Angel Muñoz7, Carmen Cantarell1, Marta Gil Calvo8, Rafael Romero8, Blanca Valenciano9, Víctor García-Nieto10, María José Sanahuja11, José Crespo12, María Luisa Justa13, Adela Urisarri14, Rafael Bedoya15, Alberto Bueno16, Antonio Daza17, Juan Bravo18, Francisco Llamas19 and Luis Antonio Jiménez del Cerro20

1Hospital Universitari Vall d’ Hebron, Barcelona, Spain, 2Hospital Universitario Cruces, Bilbao, Spain, 3Hospital Sant Joan de Déu, Barcelona, Spain, 4Hospital Universitari Clinic, Barcelona, Spain, 5Hospital Universitario 12 de Octubre, Madrid, Spain, 6Hospital Universitario Central de Asturias and Universidad de Oviedo, Oviedo, Spain, 7Hospital Universitario Virgen de la Salud, Toledo, Spain, 8Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 9Hospital Universitario Materno-Infantil Las Palmas, Las Palmas de Gran Canaria, Spain, 10Hospital Universitario Ntra. Sra. de la Candelaria, Santa Cruz de Tenerife, Spain, 11Hospital Universitario La Fe, Valencia, Spain, 12Hospital Universitario Dr Peset, Valencia, Spain, 13Hospital Universitario Miguel Servet, Zaragoza, Spain, 14Hospital Arquitecto Maricide, Ferrol, Spain, 15Hospital Universitario Virgen del Rocio, Sevilla, Spain, 16Hospital Universitario Materno-Infantil, Materno-Infantil Carlos Haya, Málaga, Spain, 17Complejo Hospitalario de Torrecárdenas, Almería, Spain, 18Hospital Universitario Virgen de Las Nieves, Granada, Spain, 19Hospital General de Albacete, Albacete, Spain and 20Hospital General Universitario de Alicante, Alicante, Spain

Correspondence and offprint requests to: Gema Ariceta; E-mail: gariceta@vhebron.net

ABSTRACT

Background. Cysteamine has improved survival and prognosis in cystinosis. Increasing numbers of patients reach adulthood and face new challenges such as compliance that wanes over time. The aim of this study was to evaluate adherence to cysteamine treatment in a group of cystinotic patients in Spain in an attempt to identify potential therapy pitfalls and improve the overall care of affected individuals. Despite the impact of cysteamine on prognosis, there is a paucity of data regarding adherence.

Method. Thirty-four cystinotic patients (21 male) 38% ≥18 years were enrolled in a voluntary, anonymous survey. Replies were obtained from patients (15/34), mothers (11/34), fathers (4/34) and both parents (4/34).

Results. Patient age (median and interquartile range) at diagnosis was 1 year (0.57–1), and patient age at Cystagon® initiation was also 1 year (0.8–1.8). Sixteen (47%) were kidney transplant (KTx) recipients; six were retransplanted. Age at first KTx 10 years (8.7–13.7). Patient understanding of multiorgan involvement in cystinosis: 41 organs reported; eye 97% and kidney 91%. Cysteamine was given by mother (100%) and father (83%) in <11 year olds, or self-administered (94%) in ≥11 year olds. Four daily doses in 89% versus 56% in <11 or ≥11 year olds, with fixed schedule in 94% versus 50% in <11 or ≥11 year olds and progressive loss of reminders over time. Furthermore, 44% complained of unpleasant smell. Motivation for treatment compliance was 100% versus 40% in <11 versus ≥11 year olds, respectively. Disease impact in patients <18 years is as follows: school (29%), social (14%), ‘feeling different’ (10%); in patients ≥18 years: ‘feeling different’ (62%), professional (39%) and job absenteeism (31%). Referring physician: paediatric nephrologist (94%) and nephrologist (63%) in <11 versus ≥11 year olds. Ophthalmological follow-up: 83% versus 50% in <11 or ≥11 year olds and progressive loss of reminders over time. Furthermore, 44% complained of unpleasant smell. Motivation for treatment compliance was 100% versus 40% in <11 versus ≥11 year olds, respectively. Disease impact in patients <18 years is as follows: school (29%), social (14%), ‘feeling different’ (10%); in patients ≥18 years: ‘feeling different’ (62%), professional (39%) and job absenteeism (31%). Referring physician: paediatric nephrologist (94%) and nephrologist (63%) in <11 versus ≥11 year olds. Ophthalmological follow-up: 83% versus 50% in <11 or ≥11 year olds. Patient opinion of physician expertise: paediatric nephrologist (94%) and nephrologist (44%). New treatment options (65%) and better information (42%) were demanded to improve adherence.

© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Conclusion. Treatment with Cystagon is effective in young patients. However, adherence diminishes over time in adolescents and adults despite disease impact. Strategies such as better information on the disease, patient self-care promotion and facilitated transition to adult healthcare services are required to improve compliance and the clinical management of cystinosis.

Keywords: adherence, cysteamine, cystinosis, prognosis, transition

INTRODUCTION

Cystinosis is a rare autosomal recessive disorder of the lysosomal cystine transporter cystinosin [1] encoded by the CTNS gene (17p13) [2], which affects ∼1–2 per 100,000 newborns [3]. Most patients exhibit the severe infantile form, leading to end-stage kidney disease (ESKD) by the end of the first decade in the absence of specific cystine-depleting treatment [1] and premature death before the second decade [4–7], whereas up to 5% present the milder late-onset form of the disease [8]. Treatment with Cysteamine (Cystagon®), the only available cystine-depleting drug from lysosomes in Spain, and renal transplantation have improved the prognosis of cystinosis [1]; consequently, increasing numbers of affected patients are reaching adulthood [9, 10]. Early and sustained treatment with cysteamine has improved renal outcome in cystinosis [11] by delaying progression to ESKD [4]. Furthermore, correct cysteamine administration also delays the onset and reduces the severity of extra-renal complications [5], leading to extended life expectancy and longer patient survival [6].

This changing scenario in cystinosis poses new challenges such as long-term compliance with a lifelong treatment [7], a difficult task in patients who take multiple medications and supplements [12], are exposed to potential cysteamine-related side effects (gastric intolerance, unpleasant smell and halitosis, among others) [13] and need to follow an ‘every 6 hour’ (Q6h) [14] dose schedule of immediately released cysteamine (Cystagon®) [15]. Last but not least, cystinosis is a good model of a rare paediatric disease extending to adult practice [4, 6, 16]; however, few resources are in place to prevent inadequate transition to adult services [17], management of systemic disease involvement is poor, reference centres are lacking in many countries and, commonly, awareness among adult physicians is low [18]. Cystinotic patients are often transferred in a suboptimal process to adult services where they feel depressed and ‘lost in the system’ [19]. New therapeutic approaches are based on a patient-centred strategy of disease education, adherence, support by patient advocacy groups and a new culture of patient ‘self-care’ [20].

MATERIALS AND METHODS

Fifty-six individuals with cystinosis under the regular care of 29 different paediatric or adult nephrologists in 22 different hospitals received chronic treatment with cysteamine (Cystagon®) in Spain in 2012. All physicians caring for a patient with cystinosis were personally invited to participate in this study so that patients and families could be informed, give their consent and be provided with a printed copy of the questionnaire.

An anonymous written survey was distributed among patients diagnosed with cystinosis at the time of a regular renal care follow-up visit at different hospitals in Spain in 2012. Patients and/or their parents, if applicable, were invited to voluntarily participate by completing a questionnaire, the estimated duration of which was ∼10 min. In order to guarantee patient confidentiality and voluntary enrolment, a ‘take home’ option was offered and patients could later submit the document to a central site, thereby preserving individual information blinded to their physicians. Patients’ geographic location or centre identification data were not provided. The survey consisted of 21 multiple-choice questions covering four main areas: (i) knowledge of cystinosis and impact of the disease; (ii) adherence to cysteamine treatment; (iii) monitoring of cysteamine therapy and (iv) measures to improve compliance. The survey was promoted by Orphan Europe (a pharmaceutical company specialized in orphan diseases and a member of the Recordati Group), which created, designed and distributed it via company representatives to physicians caring for known cystinotic patients treated with cysteamine (Cystagon®). Another firm, A.C. Nielsen Company, made the overall analysis of the results in an independent manner. The results were expressed as median and inter-quartiles and patients were divided into two groups: those under and over 11 years of age.

RESULTS

Demographics

Thirty-four paediatric and adult patients (21 male and 13 female) with nephropathic cystinosis participated in the study, a figure representing 61% of the known treated cystinotic population in Spain. The questionnaire was completed by patients (15/34), their mother (11/34), father (4/34) or both parents (4/34). Age distribution was as follows: 12 patients (35%) 0–6 years, 6 (18%) 7–11 years, 3 (9%) 12–17 years and 13 (38%) ≥18 years old. All responders suffered from the infantile form of the disease. Out of 34 (47%), 16 had received at least one kidney transplant (KTx) and 6 (18%) had more than one. Remarkably, adult patients constituted almost 40% of the study cohort; indeed, 12 of 13 patients over 18 years of age were KTx recipients and half (6/12) had received more than one graft. At the time of the study, 22 patients were being followed up in paediatric nephrology services, whereas 12 were receiving care in adult nephrology departments. The main clinical characteristics of patients are described in Table 1.

This cohort belongs to the population of cystinotic patients in Spain that currently consists of 29% children, 16% teenagers and 55% adults. However, a lower percentage of cystinotic adults was enrolled in the study because ∼32% of patients over the age of 18 did not participate.

Age at diagnosis and initiation of cysteamine

Cystinosis was diagnosed during infancy in 27 patients (79%); of them, 15 (44%) were diagnosed within the first year of life. In patients under the age of 11, treatment with
cysteamine was initiated before the second year in 89% and within the first year in 56%. A significant difference was observed in age at cysteamine initiation between patients under or over 11 years of age at the time of the study, with earlier administration in patients diagnosed more recently (median 1 versus 2.7 years old, P < 0.001) (Table 1).

**Knowledge on cystinosis and impact of the disease**
Patients were aware of the systemic nature of cystinosis and reported the almost universal involvement of organs that occurs in cystinosis such as eyes (97% responders) and kidneys (91% responders), but also others such as muscles (44%), pancreas (35%), gastrointestinal (32%), central nervous system (CNS) (32%), neurological (24%), cardiovascular (21%) and testicular (15%), with a mean of 4.1 affected organs reported per patient.

The impact of the disease on quality of life (QOL) was reported to be greater in adults than in children. Thus, 62% of affected adults complained of feeling different, 39% expressed professional limitations, 31% required job absences and 8% referred to compromised social life and rejection, whereas in patients under 18 years old, cystinosis negatively influenced school attendance (29%), learning ability (5%) and social life (14%), but only 10% reported feeling different.

**Adherence to cysteamine**
In children under the age of 11, cysteamine was mainly administered by the mother (100%) and father (83%), but also by other relatives (28%) or by a teacher or school nurse (33%). In contrast, patients over 11 were largely responsible for their own treatment (94%), with less involvement of relatives (mother 25% and father 6%) or others.

With respect to treatment adherence, 89% of patients under 11 received cysteamine (Cystagon®) following a fixed four-daily dose schedule compared with only 56% of older patients who took the correct number of four doses per day (Figure 1). Furthermore, up to 41% of patients or their relatives had asked their doctor for a reduction in the number of daily doses: 27% stated their doctors had refused to reduce the number of doses, but 15% reported their physicians had agreed.

Nevertheless, whereas the majority of children under 11 followed the cysteamine prescription correctly (94%), the percentage dropped dramatically in older patients (50%) who reported frequent schedule changes (13%), missed doses (13%), never using the recommended doses (18%) or even not caring about drug prescription (6%) (Figure 2). Although up to 65% of patients took advantage of alarms or dose-reminder tools, the study demonstrated progressive waning in their use over time, as only 46% of adult patients used dose reminders.

Regarding patient motivation for treatment, 72% of patients under 11 were always motivated, and 39% expressed more motivation before a clinical appointment. In contrast, fewer older patients expressed feeling always motivated (38%) and, remarkably, 38% expressed no motivation at all, with low increased interest before/after a clinical appointment or before a blood test (Figure 3). Patients complained of unpleasant smell (44%), too many medications (44%), excessive number of daily doses (35%) and gastrointestinal side effects (24%), among others. New therapeutic strategies focussed on lowering-frequency doses, fewer pills and/or reduced pill size (60%) as well as additional education on the disease (42%) were demanded to improve adherence to cystinosis therapy.

**Adherence to medical control**
For patients under the age of 11 years, paediatric nephrologists represented the referring physicians and 94% were considered disease experts. Remarkably, adult nephrologists were considered disease experts by only 44% of patients. Furthermore, patients stated that only 56% or 44% of paediatric or...
adult nephrologists, respectively, provided them with sufficient information regarding cystinosis. Patients were under paediatric nephrologist care up to the age of 18, after which they were progressively transferred to adult nephrologists (13 of 34 patients). Several other medical specialists were also involved in the care of cystinotic patients: ophthalmologists (62%), endocrinologists (47%), transplant physicians (27%), neurologists (15%), dermatologists (6%) and others (18%). However, whereas 83% of younger cystinotic patients received regular ophthalmology care, the percentage dropped to 38% in those over 11 years of age.

**DISCUSSION**

We were able to collect self-reported data from 61% of the cystinotic patients receiving cysteamine in Spain. This study provides an insight into the current scenario of the disease in Spain, with a significant proportion (38%) of patients over 18 years of age, mostly kidney-transplanted recipients, being under the care of adult physicians. The main findings included good compliance in children under the age of 11 and a decline in cysteamine adherence after puberty associated with less parental supervision, decreasing use of dose reminders, very low motivation rates of treatment compliance in older patients, substantial impact on QOL and inadequate transition to adult medical care [19], with many centres caring for one individual patient. Specifically, our cohort of 34 individuals was under the care of 22 different doctors working at 20 different hospitals, very telling of the dispersion of patients and consequent lack of physician/health system awareness of, and expertise in, cystinosis, which may also, at least in part, explain why a significant percentage of affected adults did not participate in the survey.

Most patients exhibit the severe infantile form of the disease and are at risk of developing premature ESKD and early death in the absence of specific cystine-depleting treatment [1], whereas up to 5% present the milder late-onset form [8]. Cysteamine treatment, which has been available since the 1980s, is able to preserve renal function and delay progression to renal failure [21] and later reduce systemic involvement of the disease [9, 10]. Oral cysteamine is able to achieve leukocyte cystine depletion of up to 95% [22, 23] and reduce the cystine parenchymal tissue content when adherence is consistent [21], with substantial beneficial effects on renal and extra-renal comorbidities [4–7] and patient life expectancy [16, 17]. Data on leukocyte cystine levels were not included in this study for their concordance with patient self-report information on adherence to be evaluated; however, the overall outcome of our cohort of cystinotic patients concurs with data of other recently published series [6, 16, 17]. Indeed, at the time of the study, 40% of cystinotic patients in this series were adults, a finding that reflects the impact of early diagnosis and cysteamine prescription in most cases. Our results also indicate an improvement in diagnosis and cysteamine initiation in this Spanish cohort of patients who started the specific treatment with Cystagon® during infancy and before 1 year of age in more than half of the contemporary new cases, a fact that presumably will be associated with better long-term outcome, as reported [5, 7, 11]. Our data also reflect the concept that cysteamine therapy should be started as early as possible after diagnosis [6, 17, 21]. Prompt diagnosis and education of parents and children from earlier ages on compliance would presumably also have a positive impact; hopefully, the children of today will be better adherents when teenagers tomorrow.

Cysteamine is known not to be able to reverse the associated Fanconi syndrome [3] or fully prevent progression to chronic kidney disease (CKD) [16–18]. We found that, even when treated, up to 47% of cystinotic patients progressed to ESKD during childhood, receiving a KTx at ~10 years of age (8.75–13.75), an experience similar to that described by the European ESPN-ERA registry [4]. In fact, almost 12 of 13 adult cystinotic patients in this series had been transplanted during childhood and retransplantation was also very common, as reported elsewhere [4, 6, 7]. Although data on renal function were not included in our survey, it seems reasonable to presume that a large number of cystinotic children also suffered CKD, as reported [10]. Therefore, most cystinotic patients would be transferred to adult KTx specialists who would need to be aware not only of this rare disease [1] but also that treatment will be lifelong, even after KTx [6, 17, 21].

This study confirms that patients understood the systemic nature of nephropathic cystinosis, with early universal kidney and eye involvement and progressive involvement of other organs such as the intestine, cardiovascular system and CNS, even after kidney transplantation [10] and mainly in low compliant individuals [6, 7], which may be beyond the scope of the
Cysteamine adherence in patients with cystinosis in Spain

CONCLUSION

Despite severity of the disease and the impact of treatment on outcome, adherence to Cystagon® wanes over time in cystinosis, particularly during adolescence and adulthood.

This study was limited by a bias of patient response, parental opinion and lack of leucocyte cystine level monitoring to ascertain actual compliance.

REFERENCES

Circulating and renal vein levels of microRNAs in patients with renal artery stenosis

Moo Yong Park1,2, Sandra M. Herrmann1, Ahmed Saad1, Robert Jay Widmer3, Hui Tang1, Xiang-Yang Zhu1, Amir Lerman3, Stephen C. Textor1 and Lilach O. Lerman1,3

1Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA, 2Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea and 3Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA

Correspondence and offprint requests to: Lilach O. Lerman; E-mail: lerman.lilach@mayo.edu

ABSTRACT

Background. MicroRNAs (miRs) are small non-coding RNAs that are important regulators of gene expression and have been implicated in atherosclerosis. Kidney injury distal to atherosclerotic renal artery stenosis (ARAS) is aggravated by atherosclerosis. Therefore, this study tested the hypothesis that renal miR expression would be altered in patients with ARAS.

Received for publication: 22.7.2014; Accepted in revised form: 18.9.2014

doi: 10.1093/ndt/gfu341
Advance Access publication 31 October 2014